1. Master Batch Record Approvals Name Signature Date Originator
|
|
- Brett Gardner
- 6 years ago
- Views:
Transcription
1 Effective: Page 1 of Master Approvals Name Signature Date Originator Ravikanth Kona Production Ravikanth Kona Quality Control Seon Hepburn Stephen Hoag Quality Assurance 2. Product Details Description Fexo A- Fexofenadine Hydrochloride 60 mg Tablets HPC: 5%; Inlet temp: 50 0 C; Compression force: 5 kn Part No. F-7046 Batch Quantity Storage Conditions Batch size: 350 gm. Approx No. tablets: Ambient - conditions, store in tight container protected from light and moisture 3. Production Issuance Issued By Issuer has reviewed the to ensure that the copy is a complete, accurate copy of the Master. Stephen W. Hoag (Print) Issued By Quality Assurance Signature Date Issued To Production has reviewed the to ensure that the copy is a complete and correct. Production is responsible for the following issuance. Ravikanth Kona (Print) Issued To - Production Signature Date
2 Effective: Page 2 of Signature and Training Log All personnel making entries on this must complete the Signature Log. Completion of the Signature Log indicates that each person has been thoroughly trained on this and all documents listed in Section 5: Reference Documentation. Note: The Signature Log completion does not supersede the requirements of GMP Training Program (SOP-006). Name Signature Initials Date Ravikanth Kona Stephen W. Hoag 5. Reference Documentation SOP-003: Good Documentation Practices SOP-006: GMP Training Program SOP-005: Nonconformances SOP-009: Material Storage and Inventory Procedure SOP-011: Facility Cleaning Procedures SOP-012: Temperature and Humidity Monitoring SOP-015: Gowning Procedures SOP-017: Retain Sample Program SOP-019: Material weighing and Dispensing SOP-020: Equipment Calibration SOP-021: s SOP-025: B2 Stokes tablet press SOP-0 SOP-0 : V- blender : Fluid bed
3 Effective: Page 3 of Bill Of Materials Description Part Number Quantity Req d Lot No. Qty Staged Exp / Retest QA Verified Fexofenadine Hydrochloride R-1057 CI Avicel PH 102 (Microcrystalli ne cellulose) Klucel EXF (Hydroxyprop yl cellulose) Lactose monohydrate 110M Mg Stearate - Kosher Passover (Covidien) Kollidon K-30 (Polyvinyl pyrollydone) Ac-Di-Sol (Croscarmell ose Na) Aerosil 200 (Aerosilized silica) R-1002 P R R R-1017 K22610 R-1013 G10976P T0 R-1016 P R Sterile water R-1038
4 Effective: Page 4 of Processing Equipment Equipment Description ID No. Previous Cal. Cal. Req d By QA Verified Fluid bed (Fluid Air model # 0002) UMB- B2-Stokes tablet press UMB /26/2010 Meets requirement UMB internal calibration Balance OHAUS CD 33 Check wt. wt. = wt. = wt. = Balance Mettler PC 440 Check wt. wt. = wt. = wt. = V- blender (Kelly Patterson) UMB- 02/23/2012 Meets requirement Mes. Wt. Toler ±0.1% Check at least 3 wts in the range to be measured UMB- 02/23/2012 Meets requirement Mes. Wt. UMB- Toler ±0.1% Check at least 3 wts in the range to be measured Meets requirement Stanley (American Scale & Equipment co Inc) If tolerance outside 0.1% range call QA Stanley (American Scale & Equipment co Inc) If tolerance outside 0.1% range call QA UMB internal calibration Timer VWR Model# UMB calibration expires 10/17/2013 Meets requirement Control Company
5 Effective: Page 5 of 17 Sieve (Cole Palmer) sizes 18 and 30 Masterflex precision pump tubing ( ) Mettler Toledo LOD equipment NA NA NA NA NA NA NA NA NA NA NA NA 8. Area Clearance Step 1. GMP Processing Area(s): Room: 2. Review the GMP Processing Area Logbook(s) and ensure that the Logbook(s) is (are) complete, and up-to-date. 3. Review all applicable GMP Processing Area Logbook(s) and verify that Cleaning and Sanitization has been performed according to Facility Cleaning Procedures (SOP-011), and that the Cleaning and Sanitizing occurred within the allowed time before a GMP operation. Date Cleaning Complete: Date Sanitizing Complete: 4. Verify that all work surfaces within the GMP Processing Area have been Sanitized (e.g., wiped with NLT 70% Isopropanol) on the day of production. Verify that this Sanitization has been recorded in the Logbook(s). 5. Review Section 6: Bill of Materials, and ensure that it is complete, accurate, and that all necessary materials are present for the GMP operation. Ensure that all GMP Materials are Released, Approved and have sufficient time to the Use By Date. QA Verified
6 Effective: Page 6 of Review Section 7: Processing Equipment, and ensure that it is complete, accurate, and that all necessary equipment is present, cleaned and calibrated, as appropriate. Review the Logbook for each piece of GMP Equipment, and ensure that the Logbooks are correctly filled out. Fluid bed (UMB-00 Twin shell blender (UMB-00 ) - ) B2-Stokes tablet press (UMB-0013) 7. Verify that the cgmp Processing Area does not contain any items from previous batches or cleaning activities and that no items unrelated to the current cgmp batch are present. 8. Area Clearance Complete. QA shall Complete the Area Clearance Sign (SOP-021, Attachment 1) and affix it to the GMP Processing Area entrance.
7 Effective: Page 7 of Weigh the API and excipients separately into a suitable container/plastic bags in Room 670. Check for lumps and screen the material if required using an 18 mesh screen. Fexofenadine Hydrochloride (R-1057) 15% Required 52.5 gm; Weighed gm. Avicel PH 102 (Microcrystalline cellulose) (R-1002) % Required gm; Weighed gm. Lactose 110M (Lactose monohydrate) (R-1012) 38.63% Required gm; Weighed gm. Ac-Di-Sol (Croscarmellose Na) (R-1016) 1.25% Required 4.38 gm; Weighed gm. Kollidon K-30 (Polyvinyl pyrollidone) (R-1013) 6.5% Note: 15% w/w solution in sterile water Required gm; Sprayed gm. Total weight of the blend (excluding the weight of the extragranular fraction) Label the container/bags - Fexofenadine blend Formulation A 2. Carefully transfer ALL the weighed materials into 8qt V- twin shell blender i.e blender UMB-00 check the fill volume once ALL the materials are transferred to the twin shell blender container. Fill volume % (visual inspection). If the fill volume is 40 to 70% of the blender - proceed to blending step (Step 6) 3. Blend for 5 min: Start Time: min; End Time: min
8 Effective: Page 8 of With a clean sampling thief (Conbar ) or spatula carefully collect 2 samples from each arm of the twin shell blender (approx 2 gm) into labeled scintillation vials (for Near infrared spectroscopy scans to test for blend uniformity). 5. Label the vial Blend + lot number 6. Note: Sample materials 3-5 cm from the surface of the powder bed with minimal disturbance to the powder bed. 7. Carefully transfer the contents of the twin shell blender into a suitable plastic bag. Note: Minimize the height of pouring to reduce segregation. 8. Label the plastic bag Fexo A blend + lot number 9. Double bag it and set it aside for Fluid bed granulation Weight of material being granulated gms. 10. Before granulation, follow area clearance steps For Fluid bed equipment set-up and operation, follow SOP Program Pyrobuttons and NIR process analyzer (please refer equipment/software manual for detail procedures) 13. Preheat Fluid bed to an air inlet temp of 50 0 C, make sure this temperature is maintained for 5 min., then charge Fexo A blend + Lot number into fluid bed
9 Effective: Page 9 of Before the granulation, record the following: Relative Humidity: (%) Temperature: ( 0 c) LOD Initial blend: (%) Initial wt of binder sol: gm Atomization pressure: psi Binder sol flow rate: gm/min Granulation start time: Pyrobutton data collection start time: NIR data collection start time: 15. During granulation increase the inlet air flow rate by 2 SCFM every 5 min. Record results in table below 16. Stop spraying the binder solution when the desired amount is added Amount of binder sol sprayed: 17. After binder solution spraying ends, lower the SCFM to 6 SCFM for the remaining of the time. ml 18. Save the NIR moisture data every 20 min
10 Effective: Page 10 of Record the following parameters every 5 min during granulation and drying. Time (min) Inlet air (SCFM) Inlet temp ( 0 c) Outlet temp ( 0 c) Product temp ( 0 c) 20. Sample approximately 1 gm of material every 5 min through the sample port to determine the moisture levels and record the following parameters. Time (min) NIR Probe ID LOD (%)
11 Effective: Page 11 of Stop the drying process when desired granule moisture content is reached. Limit: NMT 1% of starting moisture Final Moisture: (%) 22. Sieve the granules using Mesh # 18 and transferee the material into appropriate bag and label: Fexo A granules + lot number 23. Record the following parameters at the end of drying: Granulation end time: Pyrobutton data collection end time: NIR data collection end time: Final weight of granules: gm 24. Calculate yield (%) = gm 25. Read and save all the pyrobutton data
12 Effective: Page 12 of Weigh the following extragranular portion: Granules (Fexo A granules + lot no) 85% Final granulation total blend 200 g; 85% granules Required 170 gm; Weighed gm. Avicel PH 102 (Microcrystalline cellulose) (R-1002) 9% Required _ 18 _gm; Weighed gm. Klucel EXF (Hydroxypropyl cellulose) (R-1019) 5% Required _ 10 _gm; Weighed gm. Magnesium Stearate - Kosher Passover (Covidien) (R- 1017) 0.5% Required _ 1 _gm; Weighed gm. Aerosil 200 (Aerosilized silica) (R-1005) 0.5% Required _ 1 _gm; Weighed gm. 27. Sieve the extragranular excipients using Mesh # Carefully transfer ALL the weighed materials into 8qt V- twin shell blender i.e blender UMB Check the fill volume once ALL the materials are transferred to the twin shell blender container. Fill volume % (visual inspection). 30. Blend for 2 min: Start Time: min; End Time: min
13 Effective: Page 13 of Carefully transfer the contents of the twin shell blender into a suitable plastic bag. Note: Minimize the height of pouring to reduce segregation. 32. Label the plastic bag Blend for tableting: Fexo A + lot number 33. Set-up the tablet press with the hopper, feed frame and the force transducers (National instruments) attached to the computer system as described in the SOP-025. Pay careful attention to the safety notes outlined in the Operating procedures of SOP Ensure that the gap between the feed frame and the die table is paper thick (A regular A4 paper should be able to slide in and out between the die table and the feed frame) 35. Carefully pour the material (Blend for tableting: Fexo A + lot number) into the feed frame of the tablet press. 36. Manually operate/rotate the tablet press to ensure that the feed frame is evenly filled with the granules and flow well onto the die table and die cavity. 37. Continue the rotation to produce a couple of tablets - ensure that all the parts of the press are working (SOP- 025). Target weight of the tablets is 470 mg, however a range mg [Target weight = 470 mg]. 38. Power on the computer and the National Instruments chassis attached to the force transducers on the tablet press. Start the national instruments software and begin monitoring the compression forces on the tablet press (as described in SOP-025).
14 Effective: Page 14 of Turn on the tablet press, allow the machine to stabilize i.e. discard first 5 tablets and check the weight of the next 2 tablets. Adjust the height of the weight control cam to make mg tablets. 40. Using the transducers and software (National instruments) adjust the compression force to mv. 41. Throughout the collection time monitor and ensure that the compression force is within limits (Step 43). 42. Collect tablets until the end of production. Transfer these tablets into previously labeled containers Fexo A- Fexofenadine Hydrochloride USP 60 mg 43. At the end of the run perform cleaning according the SOP Post-Production Sampling, Material Transfer and Storage 11. Yield Calculations Granulation Yield Yield =100 x weight of granulation weight of powder (350 gm) Yield =
15 Effective: Page 15 of Production Comment Log Record any comments or observations from the production process. Initial and date each comment. Quality Assurance shall review, initial and date each comment or observation following production. Comment / Observation Step No QA Verified
16 Effective: Page 16 of Exception Log Record all Exceptions that occur during the production process. Quality Assurance shall review, classify, initial and date each entry following production, or as required. Planned Deviations and Nonconformances require a documented Nonconformance Report according to Nonconformances (SOP-005). Exception Documented Class (E, PD, NC) QA Verified E = Exception PD = Planned Deviation NC = Nonconformance
17 Effective: Page 17 of Post- Production Review The complete Post-Production has been reviewed for completeness and accuracy. All pages are complete and all entries conform to Good Documentation Practices. Name Signature Date Production Ravi Kona Quality Assurance Stephen W. Hoag 15. Quality Assurance Disposition The material produced through the execution of this shall be Dispositioned by QA according to Material Disposition and Status Labeling (SOP-010). The Disposition shall be recorded below. RELEASED Quantity (Units) CONDITIONAL RELEASE RESEARCH USE ONLY REJECTED (Include Comments) UMB assigned Use-By Date (MM/DD/YY or MM/YY) Comments Quantity (Units) Quantity (Units) Quantity (Units) Retest Expiration Stephen W. Hoag (Print) By - Quality Assurance Signature Date 16. Version Summary
Table 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm)
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-97 Page 1 of 5 Utility of Polyplasdone crospovidone as a Superdisintegrant Quyen Schwing, Marvin Davis, Divya Tewari, Thomas Dürig
More informationApproval Application Form for Sakura Bloom Tablets
Approval Application Form for Sakura Bloom Tablets Mock-up for Columns of Manufacturing Methods and Specifications & Test Methods for Drug Products (sample description) Study project for regulatory harmonization
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationTHE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri
THE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri Faculty of Pharmacy, Department of Pharmaceutics, Hamdard
More informationFormulation and Evaluation of Telmisartan with Hydrochlorothiazide Conventional Release Tablets
Human Journals Research Article July 2018 Vol.:12, Issue:4 All rights are reserved by S. Meena et al. Formulation and Evaluation of Telmisartan with Hydrochlorothiazide Conventional Release Tablets Keywords:
More informationReal-time tablet API analysis: a comparison of a palm-size NIR spectrometer to HPLC method
Real-time tablet API analysis: a comparison of a palm-size NIR spectrometer to HPLC method Presented by: Chris Pederson, Product Applications Engineer, JDS Uniphase Corp. Co-Authors: Nada O Brien, JDS
More informationBlank Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets) Ingredient Listing Qty. Unit NDC # Supplier. 0.
4/19/2015; Page 1 SUGGESTED FORMULATION APIs* Ingredient Listing Qty. Unit NDC # Supplier Orange Flavor (Powder) 0.40 g Stevia Powder (Stevioside) 0.20 g Bitterness Reducing Agent (NF01) Natural (Powder)**
More informationA Compilation of WHO GMP Audit Points
A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part III of VIII Current article Part III Production Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationImplementation of QBD for Analytical Methods - Session Introduction -
Implementation of QBD for Analytical Methods - Session Introduction - Sonja Sekulic January 24, 2014 Quality by Design (QbD) A Systematic Approach ICH Q8(R2) Product Profile Define quality target product
More informationTablet formulation design spaces for direct compression and roller compaction. QbD in Pharmaceutical Development: processes
QbD in Pharmaceutical Development: Tablet formulation design spaces for direct compression and roller compaction processes Morten Allesø, PhD (MSc Pharm) Pharmaceutical scientist ISPE Nordic PAT CoP, June
More informationAuditing Your Laboratory for Compliance with the FDA Dietary Supplement GMP s
Tech Tip 0020 With the advent of the cgmp s, the majority of companies are increasing the frequency of their outsourced analytical testing. But the GMPs are just that, Good Manufacturing Practices, and
More informationTable Formula of Levodopa + Benserazide HCl capsule (batch no. 004 to 008)
Introduction After using pearlitol SD (200) along with avicel ph 112 the flow of the blend was improved but still not up to the mark. Weight variation was observed around (11.47%) which was not acceptable.
More informationMalukani et al., IJPSR, 2012; Vol. 3(7): ISSN:
IJPSR (2012), Vol. 3, Issue 07 (Research Article) Received on 27 March, 2012; received in revised form 17 June, 2012; accepted 25 June, 2012 PROCESS VALIDATION OF SOTALOL HYDROCHLORIDE TABLETS J.N. Malukani*
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationTryptophan 200 mg Oral Rapid-Dissolve Tablets (Solid Suspension, mg [0.93 ml] Tablets) Ingredient Listing Qty. Unit NDC # Supplier. 0.
11/23/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Tryptophan, USP 19.200 g Raspberry Flavor (Powder) 0.50 g Stevia Powder (Stevioside) 0.20 g Bitterness Reducing Agent
More informationLABRAM Characterization Studies
LABRAM Characterization Studies Juan Osorio Fernando Muzzio Department of Chemical and Biochemical Engineering Rutgers University 10/11/2005 1 Outline Mixing principles and mechanisms. Quantification of
More informationTestosterone 20 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets) Ingredient Listing Qty. Unit NDC # Supplier
4/16/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Testosterone (Micronized), USP 1.920 g Orange Flavor (Powder) 0.40 g Vanillin Flavor (Powder) 0.20 g Stevia Powder (Stevioside)
More informationMaximizing Roller Compaction Benefits with Proper Excipient Selection
A sponsored whitepaper. Maximizing Roller Compaction Benefits with Proper Excipient Selection By: Bernhard Fussnegger, Global Development and Technical Marketing, PVP/Coatings, Instant & Modified Release,
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationPAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets. Part 1: Concept and Principles Part 2: Mock P2 Submission
PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets Part 1: Concept and Principles Part 2: Mock P2 Submission 1 Part 1 Concept and Principles Introduction Rationale Concept
More informationPharma Ingredients & Services. Ludiflash. Technical Information
Technical Information Ludiflash April 2008 Supersedes issue dated September 2007 EMP 070805e-01/Page 1 of 12 = Registered trademark of BASF SE Excipient for fast-disintegrating oral dosage forms Direct
More informationDr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur
Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended
More informationSTATE OF OHIO DEPARTMENT OF TRANSPORTATION SUPPLEMENTAL SPECIFICATION 888 PORTLAND CEMENT CONCRETE PAVEMENT USING QC/QA.
STATE OF OHIO DEPARTMENT OF TRANSPORTATION SUPPLEMENTAL SPECIFICATION 888 PORTLAND CEMENT CONCRETE PAVEMENT USING QC/QA April 15, 2011 888.01 General 888.02 Materials 888.03 Concrete Proportioning 888.04
More informationPharma Ingredients & Services. Ludiflash. Technical Information
Technical Information Ludiflash March 2012 Supersedes issue dated August 2011 03_070805e-03/Page 1 of 10 = Registered trademark of BASF group Excipient for fast-disintegrating oral dosage forms Direct
More information21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance
21CFR211 Details, Details Kirsten L. Vadheim, Ph.D., RAC 7710 196th Avenue N.E. Redmond WA 98053 Tel: 651.260.6560 Fax: 425.868.4302 klvadheim@hotmail.com 21CFR211.46 Ventilation, air filtration, air heating
More informationApplication of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013
Application of PAT for Tablet Analysis Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013 Agenda PAT@Novartis Organization Business Drivers and Cases NIR Spectroscopy for
More informationPROCESS VALIDATION OF ZOLPIDEM TARTRATE 5 mg FILM COATED TABLETS
P a g e 68 Asian Journal of PHARMACEUTICAL RESEARCH Journal homepage: - www.ajprjournal.com e-issn 2231 363X Print ISSN 2231 3621 PROCESS VALIDATION OF ZOLPIDEM TARTRATE 5 mg FILM COATED TABLETS Parixit
More informationA Framework and Case Study for Implementing the New Process Validation Guidance
A Framework and Case Study for Implementing the New Process Validation Guidance Presented By Bikash Chatterjee President and Chief Technology Officer Pharmatech Associates Agenda Introduction Comparing
More informationTABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?
WHITEPAPER TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE? { To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationCaffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets)
4/19/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Caffeine (Anhydrous), USP 9.600 g Scopolamine Hydrobromide, USP 0.050 g Mango Flavor (Powder) 0.75 g Raspberry Flavor
More informationIdentification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study
Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study Ajit S. Narang, Ph.D. Bristol-Myers Squibb, Co. 2 nd FDA/PQRI Conference on Advancing Product Quality Bethesda,
More informationPrediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using corresponding values of components
Available online at www.sciencedirect.com International Journal of Pharmaceutics 352 (2008) 202 208 Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using
More informationOptimization of a Continuous Wet Granulation Process by Understanding Granule Properties
Optimization of a Continuous Wet Granulation Process by Understanding Granule Properties Presented By Andrew Birkmire Process Development Manager GEA Process Engineering Presentation Outline Description
More informationSoluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services
Technical Information Soluplus October 2009 03_090801e-01/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 03_090801e-01 October 2009 Page 2 of 8 Soluplus 1. Introduction
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationMEETING YOUR CHALLENGES TODAY AND TOMORROW. Avicel PH BINDERS
MEETING YOUR CHALLENGES TODAY AND TOMORROW Avicel PH BINDERS FORMULA Functionality and Consistency... 02 Applications... 03 Direct compression... 03 Wet granulation... 04 Dry granulation... 04 Hard capsules...
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationStreamlined Manufacture of Modified Release Matrix Tablets via Direct Compression. Katie Hewlett, Dow Gus LaBella, Colorcon
Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression Katie Hewlett, Dow Gus LaBella, Colorcon Controlled Release Alliance Unique Together Leading polymer expertise Quality
More informationIngredient Listing Qty. Unit NDC # Supplier. Sterile Preparation
9/7/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier CollaSil OSA 18.000 g Mango Flavor (Powder) 0.90 g Raspberry Flavor (Powder) 0.48 g Vanillin Flavor (Powder) 0.24 g Stevia
More informationCalifornia Grain & Feed Industry Conference Monterey Bay January 16, 2019
California Grain & Feed Industry Conference Monterey Bay January 16, 2019 1 Page 1 Evonik Power to cr Improving Production Efficiency Presented by: Mark Daniel 2 Improving Production Efficiency Combination
More informationThe World Bank. Aide Memoire for use during GMP inspections
The World Bank e for use during GMP inspections The World Bank Procurement of Health Sector Goods Contact persons: 0 1. General information about the manufacturer Name of manufacturer Physical address
More informationScientific and Regulatory challenges in Quality by Design (QbD) submissions
Health Santé Canada Canada Scientific and Regulatory challenges in Quality by Design (QbD) submissions Krishnan R. Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences TPD, Health Canada CVG, October 2007
More informationMASTER PLANNING FOR VALIDATION
MASTER PLANNING FOR VALIDATION By: Gamal Amer, Ph.D. Principal, Premier Compliance Services, Inc. 1 Process Validation: General Principles and Practices Guidance to industry issued by the FDA in January
More informationFine dosing The fine art of fine dosing
Fine dosing The fine art of fine dosing Based on an innovative technology, Fine dosing system offers a range of high quality products with incomparable performances. Thanks to the continuous improvements,
More informationPTG-S4 Automated Powder Flow Analyzer
PTG-S4 Automated Powder Flow Analyzer The automated PTG-S4 powder testing system is used to measure the flow behavior of granules and powders in compliance with the EP , USP Pharmacopoeia
More informationSakura Bloom Tablets P2 Mock
Sakura Bloom Tablets P2 Mock Mock P2 English version Sakura Bloom Tablets Disclaimer This mock provides an example of the contents to be included in CTD 2.3.P.2 Pharmaceutical Development section for a
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Methods. Ashland Specialty Ingredients ashland.com
PHARMACEUTICAL TECHNOLOGY REPORT Ashland Specialty ashland.com PTR-96 Page 1 of 5 Utility of Polyplasdone crospovidone as a Solubilizer Quyen Schwing, Marvin Davis, Divya Tewari, Thomas Dürig Ashland Specialty,
More informationAspects of Screw Design for Wet Granulation Extrusion
Aspects of Screw Design for Wet Granulation Extrusion J. Sun, M. R. Thompson Department of Chemical Engineering, McMaster University, Hamilton, Ontario, Canada ABSTRACT This paper discusses our preliminary
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationKollidon SR: A polyvinyl acetate based excipient for DCsustained-release
Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release oral dosage forms by Dr. Bernhard Fussnegger BASF Aktiengesellschaft, Ludwigshafen Strategic Marketing Pharma Excipients Introduction
More informationRECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS
RECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS Facilities that manufacture 117, pack, or hold dietary supplements are subject to the regulations in 21 CFR Part 111, while those that manufacture, pack,
More informationKollicoat IR. The application of Kollicoat IR as a Zero Peroxide Binder for use in Solid Oral Dosage Forms. ExcipientFest.
Kollicoat IR The application of Kollicoat IR as a Zero Peroxide Binder for use in Solid Oral Dosage Forms ExcipientFest Nigel Langley Market Need Platforms Instant & Modified Release Solubilization Skin
More informationFine dosing The fine art of fine dosing
Fine dosing The fine art of fine dosing Based on an innovative technology, Fine dosing system offers a range of high quality products with incomparable performances. Thanks to the continuous improvements,
More informationProcess Validation of Sertraline Hydrochloride 50 mg tablets
International Journal of Pharmaceutical Chemistry ISSN: 2249-734X (Online) Journal DOI: 10.7439/ijpc CODEN: IJPCH3 (American Chemical Society) Research Article Process Validation of Sertraline Hydrochloride
More informationEquipment cleaning and use record
DOCUMENTATION Documentation is an essential part of the quality assurance system and, as such, should be related to all aspects of GMP. Its aim is to define the specifications for all materials and the
More informationNIRS, PAT, RTR testing EU experience and regulatory perspective
NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in
More informationStandard Operating Procedure Title: Manufacturing Instruction For Tablet Packing
Form-560 Test and Retention Sample Log Book QMS-020 Documentation Rule for GMP Documents QMS-035 Deviation Report System QMS-090 Example-Evaluation of Batch Documentation for Tablet Packing WAR-075 Example-Tablet
More informationNew Developments in Spray-Dried Lactose
New Developments in Spray-Dried Lactose Gerad Bolhuis, Klaas Kussendrager, and John Langridge* Recent advances in spraydrying technology have led to the production of new directly compressible lactose
More informationProcess Validation of Oral Solid Dosage Form-Tablet containing Anti Tubercular Agent
Available online on www.ijpqa.com International Journal of Pharmaceutical Quality Assurance; 4(3); 27-36 Research Article ISSN 05 06 Process Validation of Oral Solid Dosage Form-Tablet containing Anti
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationPrequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationAIMCAL R2R Conference 11/15/2018 1
Coating Line Operations for the Production of Drug-Containing Transdermal Patches Presented by: Ken Glade Director of Engineering LTS Lohmann Therapy Systems Kenneth.glade@lts-corp.com +1 (973) 396-5384
More informationStage 3 - Process Validation: Measuring what matters
Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationGood Weighing Practice
Good Decisions For Safe Weighing Good Evaluation Good Selection Good Installation Good Calibration Good Weighing Practice Guaranteed Quality Minimized Risk Reduced Costs Secure Audits Good Operation www.mt.com/gwp
More informationInt. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries
Review Article Process Validation of Tablet Dosage Form in Industries Ram Mohan S.R, N. Vishal Gupta* Pharmaceutical Quality Assurance group, Dept of Pharmaceutics, JSS University, Sri ShivarathreeshwaraNagara,
More informationImpact factor: /ICV: PROCESS VALIDATION OF ARTEMETHER AND LUMEFANTRINE 80/480 MG TABLET Charvi Patel*, Dinesh G. Desai, A.K.
Impact factor: 0.3397/ICV: 4.10 233 Pharma Science Monitor 6(1), Jan-Mar 2015 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com PROCESS
More informationPrequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationf a c t s T C C T B Tricalcium citrate as excipient for direct compression
f a c t s T C C T B Tricalcium citrate as excipient for direct compression Direct compression has gained enormous popularity in tablet manufacturing in recent times. It is seen as the most economic process
More informationInvestigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices
METHOCEL Application Data Partially Pregelatinized Maize Starch Investigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices ABSTRACT SUMMARY The aim of
More informationApplied Process Understanding in Drug Product Development
Applied Process Understanding in Drug Product Development A combined pharmaceutical science, materials science and chemical process engineering approach 17 October, Heidelberg, Germany ir Sander van den
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationPharma Ingredients & Services. Soluplus. Technical Information. = Registered trademark of BASF group. July 2010 Supersedes issue dated May 2010
Technical Information Soluplus July 21 Supersedes issue dated May 21 3_981e-4/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 3_981e-4 July 21 Page 2 of 8 Soluplus 1. Introduction
More informationFault tolerant control for safe plant operation. November 10, 2016
Real Time Release in Continuous Solid Dose Manufacturing: Systematic Characterization of Material Properties, and Optimal Design of Sensing and Control Methods Fault tolerant control for safe plant operation
More informationBasic Aspects of Process Validation of Solid Oral Dosage Forms
Review Article Basic Aspects of Process Validation of Solid Oral Dosage Forms Sharma Tejal Department of Pharmaceutics, B. N. Girls College of Pharmacy, Udaipur (Raj.) 313002(India) Validation of the manufacturing
More informationLifecycle Management of Process Analytical Technology Procedures
Lifecycle Management of Process Analytical Technology Procedures IFPAC 2015 Marta Lichtig Senior Scientist in New Testing Technologies, ACS Member Contents General Comparison : PV guide to NIR model development
More informationASSOCIATION POUR LA CERTIFICATION DES MATERIAUX ISOLANTS
Revision index Effective date B 15/02/2015 ASSOCIATION POUR LA CERTIFICATION DES MATERIAUX ISOLANTS 4, avenue du Recteur-Poincaré, 75782 Paris Cedex 16 Tel. 33 (0)1.64.68.84.97 Fax. 33 (0)1.64.68.83.45
More informationAMENDMENTS TO OPSS 910 (NOV 88) CONSTRUCTION SPECIFICATION FOR PRESTRESSED CONCRETE CAST-IN-PLACE 1
Works and Emergency Services CITY OF TORONTO TS 910 TRANSPORTATION SERVICES STNADARD CONSTRUCTION SPECIFICATIONS June 2001 AMENDMENTS TO OPSS 910 (NOV 88) CONSTRUCTION SPECIFICATION FOR PRESTRESSED CONCRETE
More informationTricalcium citrate as excipient for direct compression
f a c t s T C C T B Tricalcium citrate as excipient for direct compression Introduction Direct compression has gained enormous popularity in tablet manufacturing in recent times. It is seen as the most
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.1, pp ,
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.7, No.1, pp 139-147, 2014-2015 Pharmaceutical Prospective Process Validation Of Chloroquiune Tablets Vilas S Jadhav*,
More informationSTATE OF OHIO DEPARTMENT OF TRANSPORTATION SUPPLEMENTAL SPECIFICATION 888 PORTLAND CEMENT CONCRETE PAVEMENT USING QC/QA.
STATE OF OHIO DEPARTMENT OF TRANSPORTATION SUPPLEMENTAL SPECIFICATION 888 PORTLAND CEMENT CONCRETE PAVEMENT USING QC/QA April 18, 2008 888.01 General 888.02 Materials 888.03 Concrete Proportioning 888.04
More informationRoller Compaction: New trends, challenges and solutions
Roller Compaction: New trends, challenges and solutions TODD STUTZMAN, PHARM.D. R.PH. DIRECTOR, PHARMACEUTICS SARAH PYSZCZYNSKI, PH.D. PRINCIPAL SCIENTIST 21FEB2017 2017 Catalent Pharma Solutions. All
More informationProviding insight into pharmaceutical formulations
Providing insight into pharmaceutical formulations Dr Steve Ward-Smith Pharmaceutical Industry The average cost of developing a drug is reported to be approx $500 million, but up to 70% of new chemical
More informationUniversity of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester
University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester 2/26/2018 Industrial Pharmacy II, Dr. rer. nat. Rebaz Ali 1 Outlines Powder flow Introduction Factor affecting
More informationChapter 4 MATERIALS AND METHODS
Chapter 4 MATERIALS AND METHODS MATERIALS AND METHODS Chapter -4 Materials Table 4.1: Equipment used Sl. No. Name of the equipment Organization 1 Vibro sifter Ganson engineering, Mumbai 2 Octagonal blender
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationContent PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2
EMA, FDA- ANDA Readiness -OSD Generics Solution Post Formulation Development Horch Guo, May. 2016, Changzhou, China Hongxing.guo@yahoo.com Content PART I: ANDA Roadmap PART II: Understanding of CPPs &
More informationTitle Freeze-Drying cycle monitoring Problem Statement Approach Result Impact
Freeze-Drying cycle monitoring To develop hardware and software to allow the freeze drying Process variables to be monitored in real-time An electronics module was developed which uses fine filament thermocouples
More informationAmerican Association for Laboratory Accreditation
Page 1 of 34 This checklist is intended for use in association with A2LA assessments, and is not to be publicly distributed. Use of this document is restricted to A2LA employees, contractors, and applicant
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationAsian Journal of Pharmaceutical Research and Development DEVELOPMENT AND OPTIMIZATION OF IMMEDIATE RELEASE TABLET OF FEBUXOSTAT IN GOUT TREATMENT
Available online at http://ajprd.com Asian Journal of Pharmaceutical Research and Development (An International Peer-Reviewed Journal of Pharmaceutical Research and Development) Open Access to Pharmaceutical
More informationRegistered Starting Material Auditing Guide
Registered Starting Material Auditing Guide Annex 1 Aide Mémoire Company : Auditor(s) : Location, Country : Date of Audit: APIC Guide for Auditing Registered Starting Material Manufacturers Remark: Non-compliance
More informationProcess Validation And Risk Assessment Study of Loratadine Tablet
Vol: 3 Issue: 1 Process Validation And Risk Assessment Study of Loratadine Tablet *1 2 2 2 Vala Khushbu, Patel Chaitali, Rathava Rakesh, Rathod Dhara 1 Department of Pharmaceutical Chemistry, Parul Institute
More informationARIA FLUID BED PROCESSOR
ARIA FLUID BED PROCESSOR ARIA Precise parameter control and premium quality engineering are the key features of IMA Active division s fluid bed processor. Simplified processing concepts based on smart
More informationMINISTRY OF HEALTH AND SOCIAL SERVICES
MINISTRY OF HEALTH AND SOCIAL SERVICES NAMIBIA MEDICINES REGULATORY COUNCIL POST REGISTRATION AMENDMENT GUIDELINES These guidelines are meant to provide assistance to industry and health care professionals
More informationInternational Journal for Pharmaceutical Research Scholars (IJPRS)
International Journal for Pharmaceutical Research Scholars (IJPRS) V-4, I-2, 2015 ISSN No: 2277-7873 RESEARCH ARTICLE ABSTRACT Process Validation of Ibuprofen Film Coated Tablets Dukandar AD* 1, Tandel
More information